Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05710224 | Active, not recruiting | Dengue

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002)
Sponsor:

Butantan Institute

Brief Summary:

The purpose of this study is to demonstrate that V181 is safe and well tolerated and elicits an immune response that is non-inferior to that of Butantan-DV at Day 28 post-vaccination in adults 18 to 50 years of age in Brazil. The primary hypothesis is that V181 is non-inferior to Butantan-DV for each of the 4 dengue serotypes based on geometric mean titers (GMTs) and seroconversion rates at Day 28 post-vaccination.

Condition or disease

Dengue

Intervention/treatment

Q181

Butantan-DV

Phase

Phase 2

Study Type : Interventional
Estimated Enrollment : 1364 participants
Masking : Triple
Primary Purpose : Prevention
Official Title : A Phase 2, Randomized, Double-Blind, Multicenter, Safety and Immunogenicity Clinical Bridging Study to Compare V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil
Actual Study Start Date : February 15, 2023
Estimated Primary Completion Date : January 22, 2024
Estimated Study Completion Date : November 29, 2024
Arm Intervention/treatment

Experimental: Q181

Participants will receive a single 0.5 mL subcutaneous (SC) injection of V181 on Day 1.

Biological: V181

Experimental: Butantan-DV

Participants will receive a single 0.5 mL SC injection of Butantan-DV on Day 1.

Biological: Butantan-DV
Ages Eligible for Study: 18 Years to 50 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Accepts Healthy Volunteers
Criteria
Inclusion Criteria
  • Male participants are eligible to participate if they agree to the following for at least 90 days after administration of study intervention
    • Abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or
    • must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause).
    • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies
      • Is NOT women of child-bearing potential (WOCBP); or
      • is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), or
      • is abstinent from heterosexual intercourse as her preferred and usual lifestyle (abstinent on a long term and persistent basis), for at least 90 days after administration of study intervention.
      • Have a negative highly sensitive pregnancy test (urine or serum, as required by local regulations) before administration of study intervention
      • Is dengue seronegative based on a pre-vaccination point of care (POC) dengue test.
      Exclusion Criteria
      • Has a known history of dengue or Zika natural infection.
      • Has an acute febrile illness (axillary temperature ≥37.8°C) occurring within 72 hours prior to receipt of study vaccine.
      • Has a known hypersensitivity or history of severe allergic reaction (eg, swelling of the mouth and throat, difficulty breathing, hypotension or shock) to any component of the dengue vaccine, that required medical intervention.
      • Has a serious or progressive disease, including but not limited to cancer, uncontrolled diabetes, severe cardiac, renal or hepatic insufficiency, systemic autoimmune or neurologic disorder.
      • Has known or suspected impairment of immunological function, including but not limited to congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, hematologic malignancy, or treatment for autoimmune diseases.
      • Has a condition in which repeated venipuncture or injections pose more than minimal risk, such as hemophilia, thrombocytopenia, other severe coagulation disorders, or significantly impaired venous access
      • Has received a dose of any dengue vaccine (investigational or approved) prior to study entry or plans to receive any dengue vaccine (investigational or approved) for trial duration.
      • Has received a licensed non-live vaccine within 14 days before receipt of study vaccine or is scheduled to receive any licensed non-live vaccine within 28 days following receipt of study vaccine. Exception: Inactivated influenza vaccine may be administered, but must be given at least 7 days before receipt of study vaccine or at least 28 days after receipt of study vaccine.
      • Has received a licensed live vaccine within 28 days prior to receipt of study vaccine or is scheduled to receive any live vaccine within 28 days following receipt of study vaccine.
      • Has received systemic corticosteroids (equivalent of ≥2 mg/kg/day of prednisone or ≥20 mg/day for persons weighing >10 kg) for ≥14 consecutive days and has not completed treatment at least 30 days before study entry or is expected to receive systemic corticosteroids at aforementioned dose and duration within 28 days following receipt of study vaccine. (Note: topical and inhaled/nebulized steroids are permitted.)
      • Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination.
      • Has received immunosuppressive therapies, including chemotherapeutic agents used to treat cancer or other conditions, treatments associated with organ or bone marrow transplantation, or autoimmune disease, within 6 months prior to receipt of study vaccine, or plans to receive immunosuppressive therapies within 28 days following receipt of study vaccine.
      • Has received a blood transfusion or blood products (including immunoglobulins) within 6 months prior to receipt of study vaccine or plans to receive a blood transfusion or blood products (including immunoglobulins) within 28 days following receipt of study vaccine.
      • Has planned donation of blood, eggs, or sperm at any time from signing the informed consent through 90 days post-vaccination.
Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002)

Location Details

Please Choose a site

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002)

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

Brazil, Rio Grande do Sul

Hospital Tacchini (Site 0006)

Bento Gonçalves, Rio Grande do Sul, Brazil, 95700084

Not yet recruiting

Brazil, Rio Grande do Sul

University of Caxias do Sul Foundation (FUCS) - Health Research Institute (IPS) (Site 0017)

Caxias do Sul, Rio Grande do Sul, Brazil, 95070560

Not yet recruiting

Brazil, Rio Grande do Sul

ONCOSITE - Center for Clinical Research in Oncology (Site 0005)

Ijuí, Rio Grande do Sul, Brazil, 98700-000

Not yet recruiting

Brazil, Rio Grande do Sul

Hospital São Vicente de Paulo-Education and Research Management (Site 0007)

Deep step, Rio Grande do Sul, Brazil, 99010-080

Not yet recruiting

Brazil, Rio Grande do Sul

Méderi Institute for Research and Health (0020)

Deep step, Rio Grande do Sul, Brazil, 99010-120

Not yet recruiting

Brazil, Rio Grande do Sul

Teaching Hospital of the Federal University of Pelotas (Site 0009)

Pellets, Rio Grande do Sul, Brazil, 96020-360

Not yet recruiting

Brazil, Rio Grande do Sul

Brotherhood of the Santa Casa de Misericórdia of Porto Alegre-Center for Research in Infectious Diseases (Site # 003)

Porto Alegre, Rio Grande do Sul, Brazil, 90020-090

Not yet recruiting

Brazil, Rio Grande do Sul

Clinical Research Center of Rio Grande do Sul (Site 0011)

Porto Alegre, Rio Grande do Sul, Brazil, 90430-001

Not yet recruiting

Brazil, Rio Grande do Sul

LMK Serviços Médicos S/S-Reumacenter (Site 0004)

Porto Alegre, Rio Grande do Sul, Brazil, 90480-000

Not yet recruiting

Brazil, Rio Grande do Sul

Hospital Moinhos de Vento - Clinical Research Center (Site0021)

Porto Alegre, Rio Grande do Sul, Brazil, 90560-030

Not yet recruiting

Brazil, Rio Grande do Sul

São Lucas Hospital of PUCRS-HSL-PUCRS Clinical Research Center (Site 0015)

Porto Alegre, Rio Grande do Sul, Brazil, 90610-000

Not yet recruiting

Brazil, Rio Grande do Sul

Federal University of Santa Maria (UFSM) - Univer Hospital-Clinical Research Unit-UPC (Site 0001)

Santa Maria, Rio Grande do Sul, Brazil, 97105-900

Not yet recruiting

Brazil, St. Catarina

Supera Clinic (Site 0019)

Chapecó, St. Catarina, Brazil, 89812-211

Not yet recruiting

Brazil, St. Catarina

Criciuma (Site 0008)

Deep step, St. Catarina, Brazil, 88811508